Collagen Cross-linking Clinical and Oct Study

Corneal Changes After Collagen Cross-linking ; Clinical and Oct Study

1. Assessment of corneal changes in AS-OCT after collagen cross-linking (corneal thickness and demarcation line).
2. Assessment of the effect of collagen cross-linking on best-corrected visual acuity

Study Overview

• Status: Not yet recruiting
• Conditions: Corneal Ectasia of Both Eyes
• Intervention / Treatment: Device: anterior segment oct

Detailed Description

Cross-linking of collagen refers to the ability of collagen fibrils to form strong chemical bonds with adjacent fibrils. In the cornea, collagen cross-linking occurs naturally with aging due to an oxidative deamination reaction that takes place within the end chains of the collagen. It has been hypothesized that this natural cross-linkage of collagen explains why keratectasia (corneal ectasia) often progresses most rapidly in adolescence or early adulthood but tends to stabilize in patients after middle-age.

Human studies of UV-induced corneal cross-linking began in 2003 in Dresden, and early results were promising. The initial pilot study enrolled 16 patients with rapidly progressing keratoconus and all of the patients stopped progressing after treatment. Additionally, 70% had flattening of their steep anterior corneal curvatures (decreases in average and maximum keratometric values), and 65% had an improvement in visual acuity. There were no reported complications.

Per the typical cross-linking protocol, 0.1% riboflavin solution with 20% dextran is added to the de-epithelialized cornea and then photoactivated with UV-A light at 365 nm with irradiance of 3 mW/cm2 for 30 minutes. The cornea is de-epithelialized to allow adequate penetration of riboflavin into the corneal stroma. Riboflavin acts as photosensitizer; it creates free radicals, forms new molecular crosslinks, and ultimately increases the cornea's mechanical strength.

Collagen cross-linking experienced a rapid transition from laboratory procedure to clinical intervention because of the method's apparent safety and broad array of potential applications. One such clinical application is the treatment of keratoconus which is a degenerative disorder of the eye associated with thinning and subsequent bulging of the cornea, causing poor vision. Collagen cross-linking stops the progression of keratoconus in patients with mild disease, presumably by strengthening the cornea and preventing further bulging.

Collagen cross-linking has also been used successfully in the treatment of pellucid marginal degeneration and to treat iatrogenic (postoperative) ectasia. Studies have shown that CXL causes a reduction in corneal edema and thickness with improvement in visual acuity in patients with bullous keratopathy due to different causes. However, these changes last for only about six months and due to this transient effect, CXL may only have a palliative role, if at all, for now.

The effect of cross linking can be assessed postoperatively clinically and also by some devices such as Ocular Response Analyzer (Reichert Inc., Buffalo, NY, USA). The depth of treatment can be measured by the demarcation line, which usually appears at 10 to 14 days after CXL and can be monitored using corneal topography and tomography.

Optical coherence tomography (OCT) is a modality that uses low-coherence interferometry to enable non-contact, in vivo imaging of ocular structures. Since its introduction, OCT imaging has become a key part of clinical evaluation of the cornea, and the anterior eye segment.

As improvements to the technology have increased, e.g. the speed and resolution of the images captured, the impact of anterior segment OCT (AS OCT) imaging on clinical practice, has been rapidly increasing and the clinical potential of the technique in evaluating the cornea had been realized. Specific to the cornea, AS OCT now allows us to image corneal layers and structures in greater detail i.e. epithelium, Bowman's layer, stroma, Descemet membrane and endothelium.

The AS OCT is extremely useful in studying anterior segment pathology through an edematous cornea such as in Descemet membrane detachments , corneal stroma itself and corneal infiltrates secondary to infections.

AS OCT is also useful in assessing changes in cornea postoperative including corneal changes after cross linking. The most widely reported change seen on cross-sectional OCT following CXL has been the appearance of a 'demarcation' line within the corneal stroma. This line has been postulated to represent the depth of the CXL treatment, separating the treated anterior stroma and untreated posterior stroma. The demarcation line is hyper-reflective when viewed with OCT, Scheimpflug imaging and on slit lamp biomicroscopy. OCT provides the ability to measure the depth of the demarcation line and has been used as an important outcome parameter when comparing various CXL protocols. The demarcation line usually fades by three months and, in some corneas, is replaced with faint, irregular, hyper-reflective lines in the deep stroma.

Other changes that can be noted on OCT images following CXL include increased reflectivity of the treated stroma, and the appearance of fainter, secondary stromal demarcation lines.

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Doaa Aly, Master; Phone Number: +2 01061541924; Email: duaazidan75@gmail.com
• Study Contact Backup: Name: mohammed saad, professor

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

patients who underwent classic corneal collagen cross-linking

Description

Inclusion Criteria:

• patients with e corneal ectasia who are candidates for CXL.

Exclusion Criteria:

• patients with other corneal diseases not treated by collagen cross-linking
• corneal scarring.
• previous corneal surgeries (e.g intrastromal corneal ring segments)

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
corneal thickness after collagen cross linking OCT study	corneal thickness measurement in mm	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
corneal demarcation line after collagen cross linking OCT study	measurement of the depth of demarcation line from tear film in mm	12 months

Collaborators and Investigators

• Sponsor: Assiut University

Publications and helpful links

General Publications

• Wollensak G, Spoerl E, Seiler T. Stress-strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking. J Cataract Refract Surg. 2003 Sep;29(9):1780-5. doi: 10.1016/s0886-3350(03)00407-3.
• Raiskup F, Spoerl E. Corneal crosslinking with riboflavin and ultraviolet A. I. Principles. Ocul Surf. 2013 Apr;11(2):65-74. doi: 10.1016/j.jtos.2013.01.002. Epub 2013 Jan 24.
• Brummer G, Littlechild S, McCall S, Zhang Y, Conrad GW. The role of nonenzymatic glycation and carbonyls in collagen cross-linking for the treatment of keratoconus. Invest Ophthalmol Vis Sci. 2011 Aug 11;52(9):6363-9. doi: 10.1167/iovs.11-7585.
• Raiskup F, Terai N, Velika V, Sporl E. [Corneal Cross-Linking with Riboflavin and UVA in Keratoconus]. Klin Monbl Augenheilkd. 2016 Aug;233(8):938-44. doi: 10.1055/s-0042-102060. Epub 2016 Apr 7. German.

Study record dates

Study Major Dates

• Study Start (Estimated): August 1, 2023
• Primary Completion (Estimated): March 1, 2024
• Study Completion (Estimated): March 1, 2024

Study Registration Dates

• First Submitted: October 19, 2021
• First Submitted That Met QC Criteria: February 5, 2023
• First Posted (Actual): February 8, 2023

Study Record Updates

• Last Update Posted (Actual): July 19, 2023
• Last Update Submitted That Met QC Criteria: July 18, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathological Conditions, Anatomical; Dilatation, Pathologic
• Other Study ID Numbers: ant seg oct in cross linking

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No